SG11201907646YA - Proteins binding her2, nkg2d and cd16 - Google Patents

Proteins binding her2, nkg2d and cd16

Info

Publication number
SG11201907646YA
SG11201907646YA SG11201907646YA SG11201907646YA SG11201907646YA SG 11201907646Y A SG11201907646Y A SG 11201907646YA SG 11201907646Y A SG11201907646Y A SG 11201907646YA SG 11201907646Y A SG11201907646Y A SG 11201907646YA SG 11201907646Y A SG11201907646Y A SG 11201907646YA
Authority
SG
Singapore
Prior art keywords
international
lebanon
lucent
pct
drive
Prior art date
Application number
SG11201907646YA
Inventor
Gregory Chang
Ann Cheung
William Haney
Bradley Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of SG11201907646YA publication Critical patent/SG11201907646YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Prostheses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

WO 18/ 15 25 18 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIPO I PCT (51) International Patent Classification: A61K 39/00 (2006.01) Cl 2P 21/04 (2006.01) A61K 39/395 (2006.01) Cl 2P 21/08 (2006.01) C12N 5/16 (2006.01) CO7K 16/00 (2006.01) (21) International Application Number: PCT/US2018/018771 (22) International Filing Date: 20 February 2018 (20.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/461,146 20 February 2017 (20.02.2017) US (71) Applicant: ADIMAB, LLC [US/US]; 7 Lucent Drive, Lebanon, NH 03766 (US). (72) Inventors: CHANG, Gregory, P.; 143 Saunders Street, Medford, MA 02155 (US). CHEUNG, Ann, F.; 25 Mom- ingside Lane, Lincoln, MA 01773 (US). HANEY, William; 61 Lincoln Road, Wayland, MA 01778 (US). LUNDE, Bradley, M.; 7 Lucent Drive, Lebanon, NH 03766 (US). PRINZ, Bianka; 7 Lucent Drive, Lebanon, NH 03766 (US). (74) Agent: ASHRAF, Shovon et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: PROTEINS BINDING HER2, NKG2D AND CD16 (57) : Multi-specific binding proteins that bind HER2, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. omit °nolo HE lionm °nom° oimIE (10) International Publication Number WO 2018/152518 Al FIG. 1
SG11201907646YA 2017-02-20 2018-02-20 Proteins binding her2, nkg2d and cd16 SG11201907646YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762461146P 2017-02-20 2017-02-20
PCT/US2018/018771 WO2018152518A1 (en) 2017-02-20 2018-02-20 Proteins binding her2, nkg2d and cd16

Publications (1)

Publication Number Publication Date
SG11201907646YA true SG11201907646YA (en) 2019-09-27

Family

ID=63170743

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907646YA SG11201907646YA (en) 2017-02-20 2018-02-20 Proteins binding her2, nkg2d and cd16

Country Status (16)

Country Link
US (2) US11884732B2 (en)
EP (2) EP4273258A3 (en)
JP (3) JP2020508997A (en)
KR (2) KR20190120782A (en)
CN (1) CN110944661A (en)
AU (1) AU2018220736B2 (en)
BR (1) BR112019017197A2 (en)
CA (2) CA3235295A1 (en)
DK (1) DK3582806T5 (en)
ES (1) ES2955074T3 (en)
FI (1) FI3582806T3 (en)
IL (1) IL268755A (en)
MX (1) MX2019009848A (en)
SG (1) SG11201907646YA (en)
WO (1) WO2018152518A1 (en)
ZA (1) ZA201905462B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009468A (en) * 2017-02-08 2020-01-20 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer.
KR20190120782A (en) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Proteins That Bind HER2, NKG2D, and CD16
WO2018157147A1 (en) * 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
MX2020008684A (en) * 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use.
EA202091977A1 (en) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF APPLICATION
EA202091888A1 (en) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
CA3117212A1 (en) 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
PE20221404A1 (en) * 2019-08-30 2022-09-15 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTISPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D AND CD16 FOR THE TREATMENT OF CANCER
CN112029001B (en) * 2020-09-02 2022-09-06 南京北恒生物科技有限公司 Chimeric antigen receptors targeting NK activating receptors
WO2022258691A1 (en) * 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof

Family Cites Families (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
EP0415929A1 (en) 1988-01-15 1991-03-13 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
PT627940E (en) 1992-03-05 2003-07-31 Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND / OR THERAPY OF VASCULARIZED TUMORS
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69636015T2 (en) 1995-05-03 2007-01-04 Bioenhancementsments Ltd. BIS-SPECIFIC ANTIBODIES IN WHICH THE BINDING ABILITY IS INHERITIZED BY A MEDIUM-SPLITABLE GROUP REVERSIBLE
DE19531346A1 (en) 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Medicines for immunotherapy, containing antibodies that specifically recognize the MHCII antigen of a patient to be treated
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
AU1218000A (en) 1998-10-21 2000-05-08 Sunol Molecular Corporation Polyspecific binding molecules and uses thereof
US20040038339A1 (en) 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DE10156482A1 (en) 2001-11-12 2003-05-28 Gundram Jung Bispecific antibody molecule
CA2496419A1 (en) 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
DE10261223A1 (en) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Increasing the immune response through substances that influence the function of natural killer cells
RU2005127664A (en) 2003-02-06 2006-09-10 Микромет Аг (De) TRIMER POLYPEPTIDE CONSTRUCTION Inducing a Prolonged T-CELL RESPONSE
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
EP1629011B1 (en) 2003-05-31 2010-01-13 Micromet AG Human anti-human cd3 binding molecules
US7635472B2 (en) 2003-05-31 2009-12-22 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
CN100453556C (en) 2003-10-16 2009-01-21 麦克罗梅特股份公司 Multispecific deimmunized CD3-binders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
KR20060131892A (en) 2004-02-16 2006-12-20 마이크로메트 에이지 Less immunogenic binding molecules
CA2570990C (en) 2004-07-16 2014-01-21 Micromet Ag Expression-enhanced polypeptides
MX2007000723A (en) * 2004-07-22 2007-03-12 Genentch Inc Her2 antibody composition.
CA2582963A1 (en) 2004-10-01 2006-04-13 Avidex Ltd T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
DOP2006000029A (en) 2005-02-07 2006-08-15 Genentech Inc ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME)
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US20070071759A1 (en) 2005-06-29 2007-03-29 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
US20070190063A1 (en) 2005-08-19 2007-08-16 Bahjat Keith S Antibody-mediated enhancement of immune response
PE20071101A1 (en) 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
ES2856451T3 (en) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Compositions comprising specific antibodies for different species, and uses thereof
EP1934260B1 (en) 2005-10-14 2017-05-17 Innate Pharma Compositions and methods for treating proliferative disorders
US20080299137A1 (en) 2005-10-28 2008-12-04 Novo Nordisk A/S Fusion Proteins That Bind Effector Lymphocytes And Target Cells
EP1945674A2 (en) 2005-11-03 2008-07-23 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
JP2009514528A (en) 2005-11-03 2009-04-09 フレッド ハッチンソン キャンサー リサーチ センター Negative immunomodulation method of immune response by NKG2D positive CD4 + cells
ES2532124T3 (en) 2005-12-16 2015-03-24 Amgen Research (Munich) Gmbh Means and procedures for the treatment of tumor diseases
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
CN105837690A (en) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 Single-chain multivalent binding proteins with effector function
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
WO2008143954A2 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
JP2010534469A (en) 2007-07-25 2010-11-11 アストラゼネカ アクチボラグ KDR-directed targeted binding substances and uses thereof
BRPI0815416A2 (en) 2007-08-15 2014-10-21 Amunix Inc COMPOSITIONS AND METHODS FOR MODIFYING PROPERTIES OF BIOLOGICALLY ACTIVE POLYPEPTIDES
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
JP5933894B2 (en) 2007-09-14 2016-06-15 アディマブ， エルエルシー Rationally designed synthetic antibody libraries and their use
JP5591712B2 (en) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス Antibodies against human NKG2D and uses thereof
ES2774337T3 (en) 2008-01-07 2020-07-20 Amgen Inc Method for manufacturing heterodimeric Fc molecules of antibodies using electrostatic conduction effects
JP2011509687A (en) 2008-01-22 2011-03-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド RON antibodies and uses thereof
TW201006485A (en) * 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
CA2737351A1 (en) 2008-09-26 2010-04-01 Wyeth Llc Single chain antibody library design
AU2009313560B2 (en) 2008-11-07 2016-04-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
ES2550384T3 (en) 2008-12-18 2015-11-06 Dana-Farber Cancer Institute, Inc. NKG2D-Fc for immunotherapy
JP5734201B2 (en) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド Covalently bonded diabody and use thereof
AU2010233994A1 (en) 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
US20120058082A1 (en) 2009-05-13 2012-03-08 Genzyme Corporation Methods and compositions for treatment
WO2010144295A1 (en) 2009-06-09 2010-12-16 University Of Miami Aptamer-targeted costimulatory ligand aptamer
ES2536996T3 (en) 2009-07-06 2015-06-01 F. Hoffmann-La Roche Ag Bispecific Antibodies to Digoxigenin Binding
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2476752A4 (en) * 2009-09-11 2013-04-03 Takara Bio Inc Process for production of natural killer cells
AU2010311559B2 (en) 2009-10-27 2016-07-07 Amgen Research (Munich) Gmbh Dosage regimen for administering a CD19xCD3 bispecific antibody
US8999398B2 (en) 2009-11-06 2015-04-07 Transtarget Inc. Polyclonal bispecific antibody compositions and method of use
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
CA2784093A1 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
WO2011109400A2 (en) 2010-03-04 2011-09-09 Macrogenics,Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
TWI653333B (en) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 Cross-species specific PSMAxCD3 bispecific single chain antibody
RS65965B1 (en) 2010-04-20 2024-10-31 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
DK3323830T3 (en) 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center ANTI-GD2 ANTIBODIES
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
DE102010039018B4 (en) 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La antibodies and their use for immuno-targeting
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
RU2013115927A (en) 2010-09-10 2014-10-20 Апексиджен, Инк. ANTIBODIES AGAINST IL-1β AND METHODS OF APPLICATION
UY33707A (en) 2010-11-04 2012-05-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CN103429620B (en) 2010-11-05 2018-03-06 酵活有限公司 There is the antibody design of the stable heterodimeric of mutation in Fc domains
US9518132B2 (en) 2010-11-09 2016-12-13 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc Tri-variable domain binding proteins and uses thereof
WO2012115241A1 (en) 2011-02-25 2012-08-30 中外製薬株式会社 Fcγriib-specific fc antibody
MX348071B (en) 2011-03-16 2017-05-26 Amgen Inc Fc variants.
AU2012235758B2 (en) 2011-03-25 2015-05-07 Ichnos Sciences SA Hetero-dimeric immunoglobulins
WO2015070061A1 (en) 2013-11-07 2015-05-14 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
CN103842383B (en) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 Polyspecific FAB fusion proteins and its application method
NZ618016A (en) 2011-05-21 2015-05-29 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
CN103857699B (en) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 Multivalence and unit price polyspecific complex and application thereof
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
KR102049122B1 (en) 2011-06-30 2019-11-26 추가이 세이야쿠 가부시키가이샤 Heterodimerized polypeptide
DE102011118022B4 (en) 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antibodies against the prostate-specific stem cell antigen and its use
JP5938473B2 (en) 2011-07-22 2016-06-22 アフィメート テラポイティクス アーゲー Multivalent antigen-binding Fv molecule
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
SG10202102283TA (en) 2011-09-30 2021-04-29 Chugai Pharmaceutical Co Ltd Ion concentration-dependent binding molecule library
CA2859767C (en) 2011-12-19 2018-09-11 Synimmune Gmbh Bispecific antibody molecule and use thereof for treatment of proliferative disease
BR112014019459B1 (en) 2012-02-08 2023-04-18 Mcure Biosciences Inc DCIM-BINDING PROTEINS AND USES THEREOF
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
NZ799532A (en) 2012-04-20 2023-07-28 Merus Nv Methods and means for the production of ig-like molecules
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
EP2857420B1 (en) 2012-05-30 2020-09-23 Chugai Seiyaku Kabushiki Kaisha Target-tissue-specific antigen-binding molecule
EP2862875B1 (en) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
US10377827B2 (en) 2012-06-21 2019-08-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
CN110256567B (en) 2012-06-27 2023-04-25 弗·哈夫曼-拉罗切有限公司 Method for selecting and generating a customized targeting entity comprising at least two different binding entities and use thereof
JP2015528003A (en) 2012-07-13 2015-09-24 ザイムワークス，インコーポレイテッド Bispecific asymmetric heterodimer comprising anti-CD3 construct
CA2878587A1 (en) 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
CN109513003A (en) 2012-08-14 2019-03-26 Ibc药品公司 T- cell for treating disease redirects bispecific antibody
HUE042040T2 (en) * 2012-09-27 2019-06-28 Merus Nv Bispecific igg antibodies as t cell engagers
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
AU2013352812B2 (en) 2012-11-27 2019-06-20 Ajou University Industry-Academic Cooperation Foundation CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
CA2896955C (en) * 2013-01-10 2023-10-31 Genmab B.V. Human igg1 fc region variants and uses thereof
DK2943511T3 (en) 2013-01-14 2019-10-21 Xencor Inc NEW HETERODIMERIC PROTEINS
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
ES2667420T3 (en) 2013-02-05 2018-05-10 Engmab Sàrl Bispecific antibodies against cd3epsilon and bcma
SI2961771T1 (en) 2013-02-26 2020-04-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules specific to cd3 and cea
CN105189561B (en) 2013-03-14 2021-02-26 宏观基因有限公司 Bispecific molecules immunoreactive with immune effector cells expressing activating receptors and antigens expressed by virus-infected cells and uses thereof
US10858417B2 (en) * 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
DK3587448T3 (en) * 2013-03-15 2021-08-09 Xencor Inc HETERODIMER PROTEINS
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
AU2014264951A1 (en) 2013-05-10 2015-11-12 Numab Therapeutics AG Bispecific constructs and their use in the treatment of various diseases
EP3008093A1 (en) 2013-06-11 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
EP3022229A1 (en) 2013-07-15 2016-05-25 Novo Nordisk A/S Antibodies that bind urokinase plasminogen activator
AU2014290069B2 (en) 2013-07-16 2019-01-03 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
RU2671089C2 (en) 2013-09-16 2018-10-29 Хельмхольтц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treatment of bv infections and associated conditions
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
DE102013019352A1 (en) 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-specific recombinant antibody derivatives for the treatment of malignant diseases by activating an NK cell-based immune response
WO2015077891A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
CN110590950A (en) 2013-12-13 2019-12-20 基因泰克公司 anti-CD 33 antibodies and immunoconjugates
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
RU2732032C2 (en) 2013-12-20 2020-09-10 Дженентек, Инк. Double specificity antibodies
EP3327038B1 (en) 2013-12-20 2020-09-23 F. Hoffmann-La Roche AG Bispecific her2 antibodies and methods of use
US11208497B2 (en) 2013-12-23 2021-12-28 Zymeworks Inc. Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
CN106459182B (en) 2013-12-30 2021-09-03 岸迈生物科技有限公司 Tandem FAB immunoglobulins and uses thereof
RU2016132863A (en) 2014-01-15 2018-02-20 Займворкс Инк. SPECIFIC CD3 and CD19 ANTIGEN BINDING STRUCTURES
AU2015225944B2 (en) 2014-03-05 2019-07-11 Autolus Limited Chimeric antigen receptor (CAR) with antigen binding domains to the T cell receptor beta constant region
KR20160146747A (en) 2014-03-31 2016-12-21 제넨테크, 인크. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US20170022291A1 (en) 2014-04-01 2017-01-26 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Multispecific antibodies
ES2887299T3 (en) 2014-04-03 2021-12-22 Igm Biosciences Inc Modified J string
EP3129055B1 (en) 2014-04-11 2020-07-01 MedImmune, LLC Bispecific her2 antibodies
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP2942629A1 (en) 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
KR20220025917A (en) 2014-05-29 2022-03-03 마크로제닉스, 인크. Tri-specific binding molecules and methods of use thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
AU2015279316B2 (en) 2014-06-27 2021-03-04 Innate Pharma Multispecific NKp46 binding proteins
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
US11208480B2 (en) 2014-06-27 2021-12-28 Innate Pharma Multispecific antigen binding proteins
CN107109419B (en) 2014-07-21 2020-12-22 诺华股份有限公司 Treatment of cancer using CD33 chimeric antigen receptor
US10556964B2 (en) 2014-07-21 2020-02-11 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
US20170253658A1 (en) 2014-08-28 2017-09-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CA2966397A1 (en) 2014-11-03 2016-05-12 Merck Patent Gmbh Methods for generating bispecific shark variable antibody domains and use thereof
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
EP4043474A1 (en) 2014-12-05 2022-08-17 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
WO2016100533A2 (en) 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
WO2016097408A1 (en) 2014-12-19 2016-06-23 Biotecnol Limited Fusion protein comprising three binding domains to 5t4 and cd3
CN107405399B (en) 2015-01-02 2022-02-08 武田药品工业株式会社 Bispecific antibodies against plasma kallikrein and factor XII
CN107614522A (en) 2015-01-14 2018-01-19 指南针制药有限责任公司 Multispecific immune modulability antigen-binding constructs
WO2016122701A1 (en) * 2015-01-26 2016-08-04 Macrogenics, Inc. Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
AU2016219785B2 (en) 2015-02-20 2021-10-28 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
MA41613A (en) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc ANTI-DLL3 CHEMERICAL ANTIGENIC RECEPTORS AND METHODS FOR USING SUCH RECEIVERS
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016142768A1 (en) 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
CN107223135B (en) 2015-03-16 2021-11-02 亥姆霍兹慕尼黑中心-德国环境健康研究中心(Gmbh) Trispecific binding molecules for the treatment of HBV infections and related disorders
SG10201913158PA (en) 2015-04-03 2020-02-27 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
WO2016164305A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
EP3280441B1 (en) 2015-04-07 2021-09-29 Alector LLC Anti-sortilin antibodies and methods of use thereof
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
EP3297671A4 (en) 2015-05-18 2019-02-06 Eureka Therapeutics, Inc. Anti-ror1 antibodies
EP3095792A1 (en) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
WO2016191305A1 (en) 2015-05-22 2016-12-01 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
TN2017000488A1 (en) 2015-05-29 2019-04-12 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
KR102492532B1 (en) 2015-05-29 2023-01-30 아게누스 인코포레이티드 Anti-CTLA-4 Antibodies and Methods of Using The Same
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
US20160361360A1 (en) 2015-06-12 2016-12-15 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US10113003B2 (en) 2015-06-23 2018-10-30 Innate Pharma Multispecific NK engager proteins
JP6840682B2 (en) 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Multispecific antigen binding protein
KR20180027566A (en) 2015-07-06 2018-03-14 유씨비 바이오파마 에스피알엘 Tau binding antibody
US20180194861A1 (en) 2015-07-10 2018-07-12 Abbvie Inc. IgM- or IgE-Modified Binding Proteins and Uses Thereof
US11147886B2 (en) 2015-07-15 2021-10-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
WO2017011803A1 (en) 2015-07-16 2017-01-19 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
TWI793062B (en) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
JP2018531914A (en) 2015-09-14 2018-11-01 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Compositions and methods for treating cancer via CD155 / TIGIT pathway and antagonists of TGF-β
MY198560A (en) 2015-10-02 2023-09-05 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
AU2016343987B2 (en) 2015-10-29 2023-11-23 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
EP4074731A1 (en) 2015-11-04 2022-10-19 City of Hope Chimeric antigen receptors targeting her2
WO2017083545A1 (en) 2015-11-10 2017-05-18 Fred Hutchinson Cancer Research Center Nkg2d decoys
EP3374389A1 (en) 2015-11-13 2018-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
JP7091250B2 (en) 2015-12-28 2022-06-27 イナート・ファルマ・ソシエテ・アノニム Variable region of NKp46 binding protein
US20190031785A1 (en) 2016-01-13 2019-01-31 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3405492B1 (en) 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
US20170233472A1 (en) 2016-02-17 2017-08-17 Macrogenics, Inc. ROR1-Binding Molecules, and Methods of Use Thereof
US20190338013A1 (en) 2016-02-26 2019-11-07 Imunexus Pty Ltd Multi-Specific Molecules
EP3433281A1 (en) 2016-03-21 2019-01-30 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
JP7002467B2 (en) 2016-04-15 2022-01-20 マクロジェニクス，インコーポレーテッド New B7-H3 binding molecule, its antibody drug conjugate, and how to use it
WO2017177337A1 (en) 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
EP3468586B1 (en) 2016-06-14 2024-08-07 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN105906722B (en) 2016-06-24 2020-02-07 安徽未名细胞治疗有限公司 Her2 specific chimeric antigen receptor and application thereof
CA3035254A1 (en) 2016-09-01 2018-03-08 Immunomab, Inc. Bispecific antibodies
US20190225702A1 (en) 2016-10-14 2019-07-25 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
WO2018081648A2 (en) 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
CN110177803A (en) 2016-11-22 2019-08-27 T细胞受体治疗公司 For using fusion protein to carry out the composition and method that TCR is reprogramed
JOP20190134A1 (en) 2016-12-23 2019-06-02 Potenza Therapeutics Inc Anti-neuropilin antigen-binding proteins and methods of use thereof
EP3579866A4 (en) 2017-02-08 2020-12-09 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
MX2019009468A (en) * 2017-02-08 2020-01-20 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer.
JP2020507577A (en) 2017-02-10 2020-03-12 ドラゴンフライ セラピューティクス， インコーポレイテッド Protein binding to PSMA, NKG2D and CD16
BR112019016424A2 (en) 2017-02-10 2020-04-07 Dragonfly Therapeutics Inc bcma, nkg2d and cd16 binding proteins
JP2020510646A (en) 2017-02-20 2020-04-09 ドラゴンフライ セラピューティクス， インコーポレイテッド Proteins that bind to CD33, NKG2D and CD16
RU2019129511A (en) 2017-02-20 2021-03-22 Драгонфлай Терапьютикс, Инк. PROTEINS BINDING GD2, NKG2D AND CD16
KR20190120782A (en) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Proteins That Bind HER2, NKG2D, and CD16
AU2018221266A1 (en) 2017-02-20 2019-09-05 Dragonfly Therapeutics, Inc. Proteins binding CD123, NKG2D and CD16
WO2018157147A1 (en) 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN111263643A (en) 2017-05-23 2020-06-09 蜻蜓疗法股份有限公司 Proteins binding to NKG2D, CD16 and ROR1 or ROR2
AU2018273250A1 (en) 2017-05-23 2019-12-12 Dragonfly Therapeutics, Inc. A protein binding NKG2D, CD16 and a tumor-associated antigen
CN111278455A (en) 2017-05-23 2020-06-12 蜻蜓疗法股份有限公司 Proteins that bind NKG2D, CD16 and tumor-associated antigens
EA202090387A1 (en) 2017-07-31 2020-05-21 Драгонфлай Терапьютикс, Инк. PROTEINS BINDING NKG2D, CD16 AND FLT3
EP3668893A4 (en) 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1
US20200231679A1 (en) 2017-08-23 2020-07-23 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
KR20200044957A (en) 2017-09-07 2020-04-29 드래곤플라이 쎄라퓨틱스, 인크. Proteins that bind NKG2D, CD16 and tumor-associated antigens
BR112020005078A2 (en) 2017-09-14 2020-10-13 Dragonfly Therapeutics, Inc. nkg2d binding proteins, cd16, and type c lecithin-like molecule 1 (cll-1)
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
AU2019218125A1 (en) 2018-02-08 2020-08-20 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
MX2020008684A (en) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use.
TW201945390A (en) 2018-02-20 2019-12-01 美商蜻蜓醫療公司 Antibody variable domains targeting CD33, and use thereof
US20210221894A1 (en) 2018-04-03 2021-07-22 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
WO2019217332A1 (en) 2018-05-07 2019-11-14 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
KR20210010508A (en) 2018-05-16 2021-01-27 드래곤플라이 쎄라퓨틱스, 인크. Proteins that bind to NKG2D, CD16 and fibroblast active proteins
EA202091977A1 (en) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF APPLICATION
CA3108915A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
AU2020301161B2 (en) 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use
AR119393A1 (en) 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
PE20221404A1 (en) 2019-08-30 2022-09-15 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTISPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D AND CD16 FOR THE TREATMENT OF CANCER
TW202208428A (en) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 Proteins binding nkg2d, cd16 and clec12a

Also Published As

Publication number Publication date
ES2955074T3 (en) 2023-11-28
WO2018152518A1 (en) 2018-08-23
CN110944661A (en) 2020-03-31
JP2024024048A (en) 2024-02-21
KR20190120782A (en) 2019-10-24
FI3582806T3 (en) 2023-09-07
IL268755A (en) 2019-10-31
EP3582806B1 (en) 2023-07-26
JP2020508997A (en) 2020-03-26
AU2018220736B2 (en) 2024-10-24
ZA201905462B (en) 2024-07-31
EP3582806A4 (en) 2020-12-16
MX2019009848A (en) 2019-12-19
US20200231678A1 (en) 2020-07-23
EP4273258A2 (en) 2023-11-08
BR112019017197A2 (en) 2020-04-14
DK3582806T5 (en) 2024-09-02
CA3235295A1 (en) 2018-08-23
CA3054079A1 (en) 2018-08-23
EP3582806A1 (en) 2019-12-25
AU2018220736A1 (en) 2019-09-05
JP2022101687A (en) 2022-07-06
DK3582806T3 (en) 2023-09-11
US11884732B2 (en) 2024-01-30
EP4273258A3 (en) 2024-01-17
KR20240060739A (en) 2024-05-08
US20240228625A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
SG11201907646YA (en) Proteins binding her2, nkg2d and cd16
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201907638QA (en) Proteins binding cd33, nkg2d and cd16
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201907271PA (en) Proteins binding psma, nkg2d and cd16
SG11201907848YA (en) Antibodies binding to vista at acidic ph
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201907648XA (en) Proteins binding gd2, nkg2d and cd16
SG11201907870VA (en) Compositions and methods for inhibition of lineage specific proteins
SG11201808821WA (en) Agonistic antibodies that bind human cd40 and uses thereof
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201907846VA (en) Therapeutic rna
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900501RA (en) Cannabis composition
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201804134YA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof